United States of America
Dr. Swiderek has over 18 years of research and leadership experience in the biopharmaceutical industry and a proven track record of discovering and developing a wide variety of protein therapeutics. Most recently, Dr. Swiderek was Chief Scientific Officer of Theraclone Sciences, where she led development of the I-STARTM antibody discovery platform. Prior to Theraclone, Dr. Swiderek served as Vice President of Protein Science at ZymoG enetics, a Seattle -based public biotechnology company specializing in development of protein therapeutics, where she successfully built a world-class protein science department that advanced over a dozen therapeutic molecule candidates to be partnered, out-licensed and into clinical development. Prior to ZymoGenetics, Dr. Swiderek established a state-of-the-art analytical core facility at the City of Hope, National Cancer Center where she collaborated with a group of prestigious scientists. She has authored and co-authored over 60 peer reviewed articles and book chapters and has been a guest speaker at international scientific meetings and conventions.